Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was the recipient of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 2,514,268 shares, a drop of 2.6% from the November 15th total of 2,582,415 shares. Currently, 7.9% of the shares of the company are sold short. Based on an average daily volume of 89,717 shares, the short-interest ratio is presently 28.0 days.

Shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) opened at $2.05 on Tuesday. Asterias Biotherapeutics has a 52-week low of $1.95 and a 52-week high of $5.00.

AST has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating on shares of Asterias Biotherapeutics in a report on Wednesday, August 16th. Zacks Investment Research raised shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Tuesday, October 10th. Finally, ValuEngine raised shares of Asterias Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Asterias Biotherapeutics currently has an average rating of “Hold” and an average price target of $9.19.

TRADEMARK VIOLATION NOTICE: “Asterias Biotherapeutics Inc (AST) Sees Large Decrease in Short Interest” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with's FREE daily email newsletter.